<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994431</url>
  </required_header>
  <id_info>
    <org_study_id>H00018178</org_study_id>
    <nct_id>NCT04994431</nct_id>
  </id_info>
  <brief_title>Post-Operative Urinary Retention (POUR) in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin</brief_title>
  <acronym>POUR</acronym>
  <official_title>Post-Operative Urinary Retention (POUR) in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Feiran Lou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMass Memorial Health Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-Operative Urinary Retention (POUR) in Thoracic Surgery is a prospective interventional&#xD;
      study aiming to test the hypothesis that the prophylactic use of tamsulosin prior to thoracic&#xD;
      surgery in high risk patients leads to reduce the rates of POUR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-operative urinary retention (POUR) is one of the most common post-operative&#xD;
      complications encountered by most surgical specialties. The incidence of POUR can vary from&#xD;
      five to 70%.&#xD;
&#xD;
      Post-operative urinary retention is a prevalent complication. Patients who undergo thoracic&#xD;
      surgery have greater urinary retention rates compared to others. Data on effective methods to&#xD;
      reduce the risk of POUR in this high-risk group are limited.&#xD;
&#xD;
      All subjects who meet inclusion and exclusion criteria will be invited to participate. There&#xD;
      will be no randomization. All will receive tamsulosin in the pre operative period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All subjects that sign a study consent and meet inclusion and exclusion criteria will receive the the study drug.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants with Post-Operative Urinary Retention (Pour)</measure>
    <time_frame>5 days</time_frame>
    <description>Percentage of Participants experiencing Post-Operative Urinary Retention (POUR) following thoracic surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Thoracic Diseases</condition>
  <condition>Urinary Retention</condition>
  <arm_group>
    <arm_group_label>Perioperative Tamsulosin Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergoing thoracic surgery will receive 0.4mgTamsulosin Hydrochloride orally nightly for the two nights immediately prior to surgery and the morning of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Historical Comparator</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants who underwent thoracic surgery (historical). Information about occurrence of Peri-Operative Urinary Retention in thoracic surgery patients will be obtained via retrospective chart review.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin Hydrochloride</intervention_name>
    <description>0.4mg orally nightly for the two days immediately prior to surgery and the morning of surgery.</description>
    <arm_group_label>Perioperative Tamsulosin Hydrochloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All male patients &gt;=60 years old who undergo inpatient thoracic surgery for major&#xD;
             resections.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Prisoners&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  End stage renal disease on hemodialysis&#xD;
&#xD;
          -  Indwelling urinary catheter&#xD;
&#xD;
          -  Child-Pugh class C hepatic failure&#xD;
&#xD;
          -  Usage of the following medications prior to surgery: strong CYP 3A4 inhibitors, strong&#xD;
             CYP2D6 inhibitors, other alpha-adrenergic blocking agents, PDE5 inhibitors, and&#xD;
             cimetidine&#xD;
&#xD;
          -  patients known to be CYP2D6 poor metabolizers&#xD;
&#xD;
          -  History of prostatectomy or cystectomy&#xD;
&#xD;
          -  Patients with contraindications to tamsulosin and those at high risk for side effects:&#xD;
             hypersensitivity to tamsulosin HCl or any component of FLOMAX capsules,&#xD;
             hypersensitivity to sulfonamides. History of known glaucoma, hypotension, plan to&#xD;
             undergo cataract surgery in the next 2 weeks&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feiran Lou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMass Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feiran Lou, MD</last_name>
    <phone>509-334-8996</phone>
    <email>feiran.lou@umassmemorial.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shauneen Valliere, MSN</last_name>
    <phone>5083175205</phone>
    <email>shauneen.valliere@umassmed.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMass Memorial Healthcare, Inc.</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Feiran Lou</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thoracic Diseases</mesh_term>
    <mesh_term>Urinary Retention</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share data</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 24, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT04994431/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

